Literature DB >> 31071316

Long noncoding RNA XIST increases the aggressiveness of laryngeal squamous cell carcinoma by regulating miR-124-3p/EZH2.

Dong Xiao1, Xiangyan Cui1, Xin Wang2.   

Abstract

The long non-coding RNAs (lncRNAs) are an emerging class of cancer regulators. The objective of the study was to elucidate the roles and underlying mechanisms of XIST in laryngeal squamous cell carcinoma. Quantitative real-time PCR (qRT-PCR) suggested that XIST was highly upregulated in laryngeal squamous cancerous (LSCC) tissues. Knockdown of XIST, mediated by lentiviral transfection of XIST-specific short-hairpin RNA (shRNA), led to the inhibition of proliferation, migration, and invasion of LSCC cells in vitro. In vivo, XIST knockdown also suppressed the growth of LSCC xenografts in mice. Upregulation of miR-124 and downregulation of EZH2 were concomitantly observed after XIST knockdown, and our data suggested that XIST served as the competitive endogenous RNA of miR-124 to modulate EZH2 expression. Moreover, ectopic overexpression of EZH2 prominently attenuated the anti-proliferation activity by XIST knockdown. Therefore, XIST plays an important role in progression of LSCC by modulating the miR-124-EZH2 axis.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  EZH2; Laryngeal squamous cell carcinoma; lncRNA XIST; miR-124-3p

Mesh:

Substances:

Year:  2019        PMID: 31071316     DOI: 10.1016/j.yexcr.2019.04.034

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  14 in total

1.  Exosomal circPVT1 derived from lung cancer promotes the progression of lung cancer by targeting miR-124-3p/EZH2 axis and regulating macrophage polarization.

Authors:  Ying Liu; Lei Li; Xiang Song
Journal:  Cell Cycle       Date:  2022-01-13       Impact factor: 4.534

2.  Hsa_circ_0006232 promotes laryngeal squamous cell cancer progression through FUS-mediated EZH2 stabilization.

Authors:  Tianyi Wu; Guangke Wang; Xianting Zeng; Zhanwei Sun; Shichao Li; Weiwei Wang; Boyu Yu
Journal:  Cell Cycle       Date:  2021-08-26       Impact factor: 5.173

Review 3.  Potentials of lncRNA-miRNA-mRNA networks as biomarkers for laryngeal squamous cell carcinoma.

Authors:  Yan Lv; Yanhua Wang; Zhikai Zhang
Journal:  Hum Cell       Date:  2022-10-01       Impact factor: 4.374

4.  Targeting XIST induced apoptosis of human osteosarcoma cells by activation of NF-kB/PUMA signal.

Authors:  Weiliang Gao; Jisheng Gao; Longying Chen; Yande Ren; Jinfeng Ma
Journal:  Bioengineered       Date:  2019-12       Impact factor: 3.269

Review 5.  Tumor Suppressive Effects of miR-124 and Its Function in Neuronal Development.

Authors:  Rikako Sanuki; Tomonori Yamamura
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

Review 6.  X-Inactive-Specific Transcript: Review of Its Functions in the Carcinogenesis.

Authors:  Soudeh Ghafouri-Fard; Sepideh Dashti; Molood Farsi; Mohammad Taheri; Seyed Ali Mousavinejad
Journal:  Front Cell Dev Biol       Date:  2021-06-11

Review 7.  Biological Function of Long Non-coding RNA (LncRNA) Xist.

Authors:  Wenlun Wang; Lu Min; Xinyuan Qiu; Xiaomin Wu; Chuanyang Liu; Jiaxin Ma; Dongyi Zhang; Lingyun Zhu
Journal:  Front Cell Dev Biol       Date:  2021-06-10

8.  LncRNA XIST promotes the progression of laryngeal squamous cell carcinoma via sponging miR-125b-5p to modulate TRIB2.

Authors:  Chunxiu Liu; Zhenjun Lu; Hui Liu; Shenfa Zhuang; Ping Guo
Journal:  Biosci Rep       Date:  2020-04-30       Impact factor: 3.840

9.  LncRNA SNHG16 Promotes the Progression of Laryngeal Squamous Cell Carcinoma by Mediating miR-877-5p/FOXP4 Axis.

Authors:  Xiaoli Wang; Liming Liu; Wenfei Zhao; Qingyan Li; Guangsheng Wang; Huahui Li
Journal:  Onco Targets Ther       Date:  2020-05-22       Impact factor: 4.147

10.  LncRNA LINC-PINT Inhibits Malignant Behaviors of Laryngeal Squamous Cell Carcinoma Cells via Inhibiting ZEB1.

Authors:  Xianguang Yang; Susheng Miao; Xionghui Mao; Cheng Xiu; Ji Sun; Rong Pei; Shenshan Jia
Journal:  Pathol Oncol Res       Date:  2021-04-01       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.